Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment
China-based biotech company Akeso Biopharma (HKG: 9926) announced that its self-discovered bispecific antibody (BsAb) cadonilimab...
Drug
Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical...
Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China
The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...
Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines
China-based Jiangsu Recbio Technology Co., Ltd has announced receiving clinical trial approval from the Food...
Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment
US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...
Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate...
Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...
Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory...
Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...
Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022
China-based Ascletis Pharma Inc. (HKG: 1672) presented the latest results of a Phase IIb clinical...
Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced receiving approval from the ethics...
GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis
UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch...
Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review
China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...
Takeda Pharmaceutical’s Teduglutide Filed for Marketing Approval in China
The Center for Drug Evaluation (CDE) website in China indicates that Japan-based Takeda Pharmaceutical Co.,...
Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial
China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s...
Antengene Receives Australian TGA Approval for ATG-018 Clinical Trial
China-based biopharma Antengene Corporation (HKG: 6996) has announced receiving approval from the Therapeutic Goods Administration...
Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors
Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...
RemeGen’s Telitacicept Begins Global Phase III Trial for Severe SLE
China-based pharmaceutical firm RemeGen (HKG: 9995) has announced the first patient dosing in a global...
BrightGene Bio-Medical Technology Gains NMPA Approval for Oseltamivir Dry Suspension
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced receiving market approval from the...
Rakuten Medical Taiwan Administers First Dose of ASP-1929 in Phase II Trial
Rakuten Medical Taiwan Inc. announced the administration of its photo-immunotherapy ASP-1929 to the first patient...